Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C

Arquivos de Gastroenterologia

Volumn 41, Issue 2, 2004, Pages 132-133

  Martins Jr , Elson Vidal ^a,b   Gaburri, Ana K ^a  

^a UNIVERSIDADE METROPOLITANA DE SANTOS   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOMYSIUM ANTIBODY; GLIADIN ANTIBODY; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; CASE REPORT; CELIAC DISEASE; DUODENUM; FEMALE; GENOTYPE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INTESTINE VILLUS ATROPHY; MALABSORPTION; MALAISE; SCREENING; SIDE EFFECT;

EID: 7044273940     PISSN: 00042803     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-28032004000200012     Document Type: Article

References (18)

1. Adinolfi LE, Mangoni ED, Andreana A. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease. Am J Gastroenterol 2001;96:607-8.
2. Bardella MT, Marino R, Meroni PL. Celiac disease during interferon treatment. Ann Intern Med 1999;131:157-8.
3. Berti I, Trevisol C, Tommasini A, Citta A, Neri E, Geatti O, Ventura A, Not T. Usefulness of screening program for celiac disease in autoimmune thyroiditis. Dig Dis Sci 2000;45:403-6.
4. Bourliere M, Oules V, Perrier H, Mengotti C. Onset of celiac disease and interferon treatment. Lancet 2001;357:803-4.
5. Cammarota G, Cuoco L, Cianci R, Fedeli G, Gasbarrini G. Onset of celiac disease during treatment with interferon for chronic hepatitis C. Lancet 2000;356:1494-5.
6. Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999;53:242-54.
7. Farrel RJ, Kelly CP. Celiac sprue. N Engl J Med 2002;346:180-8.
8. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001;120:636-51.
9. Fine KD, Ogunji F, Saloum Y, Beharry S, Crippin J, Weinsten J. Celiac sprue: another autoimmune syndrome associated with hepatitis C. Am J Gastroenterol 2001;96:138-45.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Jr FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
11. Gandolfi L, Pratesi R, Cordoba JCM, Tauil PL, Gasparin M, Catassi C. Prevalence of celiac disease among blood donors in Brazil. Am J Gastroenterol 2000;95:689-92.
12. Kumar V, Rajadhyassha M, Wortsman J. Celiac disease-associated autoimmune endocrinopathies. Clin Diagn Lab Immunol 2001;8:678-85.
13. Melo SBC, Galvão LC, Fernandes MIM, Peres LC, Maranho DAC. Prevalência de doença celíaca em doadores de sangue em Ribeirão Preto. Pediatrika 2003;23:244-73.
14. Not T, Horvath K, Hill TD, Partanen J, Hammed A, Magazzu G, Fasano A. Celiac disease risk in the USA: high prevalence of antiendomysium antibodies in healthy blood donors. Scand J Gastroenterol 1998;33:494-8.
15. Shuppan D. Current concepts on celiac disease pathogenesis. Gastroenterology 2000;119:234-42.
16. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a type 1 citokine profile. J Hepatol 1999;30:376-82.
17. Utiyama SRR, Kotze LMS, Nisihara RM, Carvalho RF, Carvalho EG, Sena MG, Reason IJTM. Spectrum of autoantibodies in celiac patients and relatives. Dig Dis Sci 46:2624-30.
18. Volta U, De Francheschi L, Molinaro N, Cassani F, Muratori L Lenzi M, Blanchi FB, Czaja AJ. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998;43:2190-5.